Leukemia Research

Aims & Scope

Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies.

The editors encourage the submission of articles relevant to hematological malignancies.

The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.2
2024	2.10

SJR (SCImago Journal Rank)

Year	Value
2024	0.784

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	98

Journal Rank

Year	Value
2024	6971

Journal Citation Indicator

Year	Value
2024	657

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Diagnostic criteria and classification of mastocytosis: a consensus proposal

  Citation: 902

  Authors: Peter, Hans-P, Luis, B.Jack, Chin Y, Lawrence B, Gianni, Rosa, Cem, Karl, Wolfgang R, Klaus, Richard D, Reza M, K.Frank, Karl, Dean D, James W, John M

• Establishment of an immature mast cell line from a patient with mast cell leukemia

  Citation: 566

  Authors: J.H., D., G., G.J.

• Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI or FcγRI

  Citation: 437

  Authors: Arnold S., Cem, Yalin, Menachem, Julie P., Michael A., V.Koneti, Dean D.

• Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

  Citation: 411

  Authors: Peter, Hans-Peter, John M., Christa, Ulrich, Peter, Torsten, Detlef, Hans-Jochen, Otto, Michael, Arjan, Kiyoyuki, Alberto, Michael, Björn, Wolfgang R., Reinhard, Denise A.

• In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

  Citation: 311

  Authors: Paul, Sharon, Natashia, Sherwin, Troy, Natalia, Pierrot, David, Lawrence

• A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

  Citation: 297

  Authors: James D., David, Kert, Peter, Stuart F.

• Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy

  Citation: 255

  Authors: B.Jack, Maria Jose, Yongsheng

• BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review

  Citation: 242

  Authors: Xin, Amit K., Yibo, Pei-Rong, Charles R., Zhe-Sheng

• 1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells

  Citation: 241

  Authors: Donald M., Jesus F., Hedley C., Philip M., Heddy, Daniel, John M.

• MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation

  Citation: 240

  Authors: Alessandra, Michela, Antonella, Alda, Paola, Daniela, Alessandra, Giovanna, Ulf, Kenneth, Federico

---